We are committed to driving progress for the Alzheimer’s disease community and look forward to the FDA’s review of our filing.” Biogen shares were marked 4.75% higher in early trading Wednesday to change hands at $281.15 each, a move that would trim the stock's year-to-date decline to around 4%.Earlier this year,  Eli Lilly & Co.  (LLY) - Get Report said trial of solanezumab, a drug used to treat patients with, or who are at risk for, dominantly inherited Alzheimer's disease failed to meet the primary endpoint set for the multi-year study, which was conducted with Switzerland's Roche.